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Purpose: Uveal melanoma (UM) is the most common primary cancer of the eye, resulting not only in vision loss, but
also in metastatic death. This study attempts to identify changes in the patterns of gene expression that lead to malignant
transformation and proliferation of normal uveal melanocytes (UVM) using the Suppressive Subtractive Hybridization
(SSH) technique.
Methods: The SSH technique was used to isolate genes that are differentially expressed in the TP31 cell line derived from
a primary UM compared to UVM. The expression level of selected genes was further validated by microarray, semi-
quantitative RT–PCR and western blot analyses.
Results: Analysis of the subtracted libraries revealed that 37 and 36 genes were, respectively, up- and downregulated in
TP31 cells compared to UVM. Differential expression of the majority of these genes was confirmed by comparing UM
cells with UVM by microarray. The expression pattern of selected genes was analyzed by semi-quantitative RT–PCR and
western blot, and was found to be consistent with the SSH findings.
Conclusions: We demonstrated that the SSH technique is efficient to detect differentially expressed genes in UM. The
genes identified in this study represent valuable candidates for further functional analysis in UM and should be informative
in studying the biology of this tumor.
Uveal melanoma (UM) is a malignant tumor that arises
from neural crest-derived melanocytes of the uveal tract of the
eye [1]. It is the most prevalent primary cancer of the eye with
an annual frequency of 4–7 cases per million of population in
North America [1]. This ocular tumor not only has the capacity
to destroy vision but can also metastasize and ultimately cause
death in up to half of patients diagnosed with this type of
cancer. Despite chemotherapy, the metastatic disease is fatal,
usually within a few months of diagnosis [1].
Carcinogenesis occurs as an accumulation of molecular
events involving disruption of cell cycle and apoptotic control,
as  well  as  increased  aneuploidy  leading  ultimately  to
malignant transformation and dissemination of tumor cells. In
the past decade, many details of the pathogenesis of UM have
emerged, e.g., the gene-expression signatures with prognostic
significance, as well as guanine nucleotide-binding proteins
alpha-q and alpha 11 (GNAQ/GNA11) and BRCA1 associated
protein-1 (BAP1) mutations [2-5]. Despite these discoveries,
a better insight into tumor progression of UM primary tumors
remains of utmost importance to identify new therapeutic
targets.  One  way  to  better  understand  the  malignant
transformation  of  cells  is  to  determine  which  genes  are
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differentially expressed between primary tumors and normal
melanocytes.
The  suppressive  subtractive  hybridization  (SSH)
technique,  a  combination  of  subtraction  and  kinetic
enrichment coupled to subsequent amplification, increases the
representation of rare mRNAs, which enables to compare two
different populations of mRNAs and to obtain clones of genes
that are differentially expressed in the population of interest
[6,7]. This technique has proven to be useful in identifying
tissue-specific and less abundant transcripts as it can achieve
over  a  1,000  fold  enrichment  for  differentially  expressed
cDNA populations [6,8]. Here, we describe the identification
of 73 genes differentially expressed in primary UM using the
SSH technique. Some of these genes are likely involved in
malignant  transformation  and  should  be  informative  in
studying the biology of UM.
METHODS
This  study  followed  the  principles  of  the  Declaration  of
Helsinki  and  was  approved  by  our  institutional  human
experimentation committee. Written informed consent was
obtained from the enucleated subjects.
Tissue collection and cell culture: The TP31 cell line is
derived from a mixed epitheloid-spindle primary UM tumor
of a 62-year-old patient that died of liver metastases (Table 1)
[9].  This  cell  line  does  not  have  mutations  in  GNAQ  or
GNA11  and  was  cultured  in  DMEM/F12  medium  (Gibco
BRL, Burlington, ON) supplemented with 10% FBS (Gemini;
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1324NorthBio,  Toronto,  ON)  under  5%  CO2.  Normal  uveal
melanocytes (UVM) were grown from human donor eyes
provided by the Banque d’Yeux Nationale (CHUL, Québec,
QC), according to the procedure described by Hu et al. [10].
Samples of UM primary tumors were collected at the time of
enucleation (Table 1) and were either immediately stored at
−80 °C in Tri-Reagent for RNA extraction (Sigma-Aldrich,
Oakville,  ON)  or  grown  in  tissue  culture  for  less  than  9
passages  [9].  Tumors  were  classified  according  to  a
modification of the Callender’s classification [11].
Suppressive subtractive hybridization (SSH): Total RNA
derived from both the TP31 cell line and UVM (pool of 18
donors)  was  extracted  with  the  RNeasy  kit  (Qiagen,
Mississauga, ON) and mRNA was isolated with the Oligotex
mRNA  kit  (Qiagen)  according  to  the  manufacturer’s
instructions. cDNA was synthesized using the SMART PCR
cDNA Synthesis kit (Clontech Laboratories, Mountain View,
CA). Two SSH libraries were then performed between the
TP31 cell line and UVM (a forward subtraction named “TP31
cell line subtracted library” and a reverse one named “UVM
subtracted library”) using the PCR-Select cDNA Subtraction
kit  (Clontech  Laboratories)  according  to  the  procedure
described by Diatchenko et al. [7]. In the forward subtraction,
the TP31 cell line was used as the tester and UVM as the driver
(TP31  cell  line  subtracted  library,  which  corresponds  to
upregulated genes in the TP31 cell line) whereas the UVM
were used as the tester and the TP31 cell line as the driver in
the  reverse  subtraction  (UVM  subtracted  library,  which
corresponds to downregulated genes in the TP31 cell line). To
evaluate  the  efficiency  of  the  cDNA  subtraction,  the
expression  level  of  actin  and  endothelin  receptor  type  B
(EDNRB; Table 2) was monitored by RT–PCR in subtracted
cDNA and unsubtracted cDNA. Aliquots of subtracted and
unsubtracted cDNAs were removed from each reaction after
18,  23,  28,  and  33  cycles  and  compared  by  agarose  gel
electrophoresis.
Cloning, differential screening, sequencing and analysis
of  the  subtracted  cDNAs:  The  PCR  products  of  the  SSH
libraries  were  purified  (NucleoSpin  Extract  kit;  Clontech
Laboratories) and then inserted into the T/A cloning vector
pGEM-T  Easy  (Promega,  Madison,  WI).  Individual
transformants  carrying  subtracted  cDNA  fragments  were
isolated  from  white  colonies  and  used  for  differential
screening (PCR-Select Differential Screening kit; Clontech
Laboratories) to eliminate false positives, according to the
manufacturer’s instructions. PCR fragments of the positive
clones  were  isolated  with  QIAquick  PCR  Purification  kit
(Qiagen) and then sequenced using Nested PCR Primers 1 and
2R  (Clontech  Laboratories)  with  an  automated  DNA
sequencer  (ABI  Prism  model  3900;  Applied  Biosystems,
Foster City, CA). DNA sequencing of positive clones was
performed by the Plateforme de séquençage et de génotypage
TABLE 1. CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL DATA OF UVEAL MELANOMA CASES.
# Age, Sex Size Last status Follow-up*
(months)
Pathology
TP31 62, M Large Dead of metastasis 42 Mixed
1 69, M Large Alive without metastasis 104 Mixed
2 33, M Large Alive without metastasis 104 Spindle
3 45, M Medium Alive without metastasis 81 Spindle
4 34, F Medium Alive without metastasis 103 Spindle
5 69, M Small Alive without metastasis 57 Spindle
6 46, M Large Dead of metastasis 18 Epithelioid
*Follow-up: period from enucleation until patient death or last visit.
TABLE 2. SEQUENCE OF FORWARD AND REVERSE PRIMERS USED FOR PCR AMPLIFICATION.
Gene Forward primer (5′-3′) Reverse primer (5′-3′) Expected PCR product
size (bp)
Actin TGTCCACCTTCCAGCAGATGT CACTCCCAGGGAGACCAAAA 609
ANLN CCAAGTCCTGTGTCCTCA TGTCCCTCACAACTTTTAGCA 643
ANP32E CGCGCTAGTGTGTGGACAAG CGGCGCTTCATTATCCTCCT 700
CKAP5 CAGTGAGTGGTTGAAACTGCC CTCCAGGGCCTCTTTTCTC 895
CTSK ACCCCGGTTCTTCTGCACAT GCCGAGGTACCCCTGTCTCA 306
DTL CTTGGCGTCCTGAGAAATGG TGGAAATCCACAGAAGGAGCA 614
EDNRB CCAACATGTGGCCCAGCCTA TGAGGTGGGGTTGGAGGAAA 231
MTAP AGTAGCATGGCTGCCCAGGA CCCTCCACCCTTTATTGTTGC 310
PPP3CA AGGCAATTGATCCCAAGTTGT GGGGTAGAGAATTTTCAAGGC 409
TSPYL5 AGATGCAAGGGAAAGGAAGCA CTCGGACCCCATGTGTCCAT 323
TYRP1 ACCGCTGTGGCTCATCATCA TCCCCGTTGCAAAATTCCAG 603
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1325des génomes at Université Laval (Québec, QC). The inserted
sequences were examined for similarities to human genes with
the NCBI BLAST program. Poly (A)+, vector sequences, and
sequences with many ambiguities were manually removed
from  the  sequence  data.  A  sequence  was  considered
significant to a database entry when an aligned region was
more than 95% identical over the entire cDNA length.
Microarray gene expression profiling: Gene expression
profiling was performed as previously reported [12] using
HumanHT-12  v3  Expression  BeadChip  arrays  (48,804
probes; Illumina, San Diego, CA). Data were analyzed using
the ArrayStar v3.0 software (DNASTAR, Madison, WI).
Semi-quantitative RT–PCR: Total RNA derived from the
TP31 cell line, as well as from UVM was extracted with the
RNeasy kit (Qiagen) as described above. Total RNA derived
from uncultured UM primary tumors was isolated using Tri-
Reagent  (Sigma-Aldrich,  Oakville,  ON)  according  to  the
manufacturer’s  instructions.  Reverse  transcription  was
performed  using  random  hexamer  primers  following
manufacturer’s protocol for synthesis of first strand cDNA
(MBI Fermentas, Burlington, ON). Primers (Table 2) were
designed using the GenBank database (NCBI, Bethesda, MD).
Semi-quantitative  RT–PCR  was  performed  as  described
previously  [13]  using  the  QuantumRNA  18S  Internal
standards protocol (Ambion, Austin, TX) according to the
manufacturer’s instructions.
SDS–PAGE  and  western  blot:  Protein  extraction  and
SDS–PAGE/western  blot  were  performed  as  described
previously  [14].  Proteins  were  separated  on  10%
polyacrylamide  gels,  transferred  onto  a  nitrocellulose
membrane  (Biorad,  Hercules,  CA)  and  incubated  with
antibodies directed against β-actin (loading control; mouse,
0.025 µg/ml; Cedarlane, Hornby, ON), anillin (ANLN; rabbit,
1.0 µg/ml; kindly provided by Dr. Peter A. Hall, Queens
University, Belfast, Ireland), protein phosphatase 3 catalytic
subunit  alpha  isoform  (PPP3CA;  rabbit,  1.0  µg/ml;
Chemicon, Temecula, CA) and tyrosinase-related protein 1
(TYRP1; rabbit, 0.08 µg/ml; Santa Cruz Biotechnology, Santa
Cruz, CA). The blots were visualized using the Fluor-S Max
System  (Biorad,  Hercules,  CA)  after  incubation  with
peroxidase-conjugated secondary antibodies.
RESULTS
Evaluation of subtraction efficiency: Successful SSH should
decrease housekeeping gene transcripts abundance and enrich
tissue-specific  gene  transcripts  [6].  A  reduction  of  actin
mRNA expression can be observed in the TP31 subtracted
library compared to the unsubtracted TP31 cDNA. Indeed, the
actin  amplicon  can  be  observed  after  23  cycles  of
amplification in the subtracted library compared to 18 cycles
for  the  unsubtracted  population  (Figure  1A).  A  similar
reduction of actin mRNA expression was observed in the
UVM subtracted library (Figure 1B). As a positive control for
the enrichment of differentially expressed genes, EDNRB, a
melanocytic lineage marker was amplified. EDNRB amplicon
can be observed after 18 cycles in the UVM subtracted library
compared to 33 cycles for the unsubtracted population (Figure
1C). These data demonstrate successful subtractions, with
significant  reduction  of  actin  abundance  and  significant
enrichment of EDNRB, 5 cycles corresponding roughly to a
20-fold cDNA concentration difference.
Comparison of mRNA profiles between uveal melanoma and
normal uveal melanocytes using SSH: The analysis of the
TP31 cell line subtracted library (UM upregulated genes)
showed that 58 positive clones corresponded to 37 genes when
taking the redundancy into account (Table 3). 57% of these
genes were previously associated with cancer (highlighted in
bold in Table 3). The most highly represented genes in this
subtracted library were anillin (ANLN) and the cytoskeleton
associated  protein  5  (CKAP5).  Analysis  of  the  UVM
subtracted library (UM downregulated genes) showed that 54
positive clones corresponded to 36 genes when taking the
redundancy into account (Table 4). Among these genes, 55%
were  previously  found  to  be  downregulated  in  cancer
(highlighted in bold in Table 4). The most highly represented
genes in the UVM subtracted library were actin gamma 1
(ACTG1),  alpha-2-macroglobuline  (A2M),  cathepsin  K
(CTSK), and proteolipid protein 1 (PLP1). Comparison with
microarray data of the previously published transcriptome of
UVM [12] confirmed an upregulation of 70% of the genes
identified  in  the  TP31  cell  line  subtracted  library  and  a
downregulation of 81% of the genes identified in the UVM
subtracted library (Table 3 and Table 4, last column). The
most represented biologic processes were associated to cell
division and metabolism for the upregulated genes, while they
were linked to differentiation and G-protein signaling for the
downregulated genes.
Validation of selected up- and downregulated genes by semi-
quantitative  RT–PCR  and  western  blot:  Semi-quantitative
RT–PCR analyses were performed to compare the expression
of the upregulated genes acidic nuclear phosphoprotein 32
member  E  (ANP32E),  CKAP5,  and  denticleless  homolog
(DTL) from the TP31 cell line subtracted library (Figure 2A),
as  well  as  the  downregulated  genes  CTSK,
methylthioadenosine  phosphorylase  (MTAP),  and  testis-
specific protein-like 1 y-encoded (TSPYL5) from the UVM
subtracted library (Figure 2B) between the TP31 cell line, UM
primary tumors, and UVM. These genes were chosen for their
redundancy in the SSH libraries and/or their implication in
malignant  melanoma  or  other  cancers,  after  microarray
validation.  These  analyses  showed  identical  expression
patterns as those revealed by the SSH technique, indicating
that the SSH data were accurate. Indeed, no band could be
seen in the UVM for the upregulated genes (Figure 2A). In
addition, no band could be observed in the TP31 cell line and
UM primary tumors for the downregulated genes (Figure 2B).
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1326We next examined both mRNA and protein expression of
ANLN  and  TYRP1  between  TP31  cell  line,  UM  primary
tumors, and UVM (Figure 3). Neither mRNA nor protein
could be detected for ANLN in UVM compared to TP31 and
some primary tumors (Figure 3A). TYRP1 mRNA and protein
level were greatly decreased in TP31 cell line and primary
tumors  compared  to  UVM  (Figure  3B).  In  addition,
PPP3CA  mRNA  or  protein  was  not  detected  in  UVM
Figure 1. Evaluation of the subtraction
efficiency  by  PCR  using  the
housekeeping  gene  actin  and  the
melanocyte  marker  EDNRB.  A:
Reduction  of  actin  expression  in  the
TP31  subtracted  library  compared  to
unsubtracted TP31 cDNA. B: Reduction
of  actin  expression  in  the  UVM
subtracted  library  compared  to
unsubtracted  UVM  cDNA.  C:
Enrichment of EDNRB expression in the
UVM  subtracted  library  compared  to
unsubtracted  UVM  cDNA.  Samples
were taken after 18, 23, 28, and 33 PCR
cycles.
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1329compared to TP31 and primary tumors (Figure 4). Moreover,
we identified a new splice variant of PPP3CA in the TP31 cell
line as well as in the primary tumors. This shorter amplicon
was not expressed by the UVM (Figure 4A, lower band). The
sequencing of this amplicon allowed the identification of a
new splice variant of PPP3CA lacking exon 2 (PPP3CAΔ2).
Western blots were performed to confirm the existence of a
splice variant of the PPP3CA protein using an antibody raised
against exon 1 to assess the expression of both the native
protein and the splice variant lacking exon 2. As can be seen
in Figure 4B (left panel), two protein products were detected
at 51- and 59-kDa in the extracts prepared from both the TP31
cell line and a pool of UM primary tumor protein extracts, but
not  in  UVM.  When  using  several  UM  primary  tumors
separately, some expressed both the native PPP3CA protein
and the splice variant, while others expressed only the splice
variant (Figure 4B, right panel).
DISCUSSION
Only a few oncogenes involved in the development of UM
primary tumors have been discovered until now. This study
was undertaken to identify additional genes that could be
required  for  malignant  transformation  of  melanocytes  by
preparing subtracted libraries using normal UVM and the UM
cell line TP31. The sequencing of upregulated cDNAs from
the  TP31  cell  line  subtracted  library  and  downregulated
Figure 2. Validation of upregulated and
downregulated genes identified in the
subtracted  libraries.  The  mRNA
expression level of selected genes was
measured  by  semi-quantitative  RT–
PCR in the TP31 cell line, a pool of RNA
from  uncultured  UM  primary  tumors
(Tumors)  and  UVM.  A:  Upregulated
genes identified in the TP31 subtracted
library  (ANP32E,  CKAP5,  DTL).  B:
Downregulated genes identified in the
UVM subtracted library (CTSK, MTAP,
TSPYL5). The 18S rRNA was used as an
internal  control  of  amplification  (489
bp).  Data  are  representative  of  three
independent experiments.
Figure 3. ANLN and TYRP1 expression
in  UM.  A:  The  expression  level  of
ANLN  was  measured  by  semi-
quantitative RT–PCR (left panel) and
western blot (right panel) in the TP31
cell line, UM primary tumors (Tumors),
and UVM. B: The expression level of
TYRP1  was  measured  by  semi-
quantitative RT–PCR (left panel) and
western blot (right panel) in UVM, the
TP31 cell line and UM primary tumors
(Tumors). The 18S rRNA was used as
an internal control of amplification (489
bp). Actin was used as a protein loading
control. Data are representative of three
independent experiments.
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1330cDNAs from the UVM subtracted library has resulted in the
identification of 73 genes differentially expressed by UM.
Many genes found to be upregulated in the TP31 cell line
subtracted library were previously associated with cancer,
including ANLN and PPP3CA. ANLN is an actin binding
protein that can associate with septins and is involved in
cytokinesis  [15].  Several  studies  have  demonstrated  an
overexpression of ANLN in cancer such as in several of the
UM tumors assayed in the present study. Indeed, Hall et al.
assessed ANLN expression in several human tissue samples
and cell lines by microarray analyses and demonstrated that
the median level of ANLN expression was higher in tumors
than  in  normal  tissues  and  correlated  with  the  metastatic
potential  of  these  tumors  [16].  Moreover,  ANLN
overexpression was shown to increase levels of active RhoA
and  subsequently  cell  motility  [16].  Therefore,  given  that
increased genomic instability is a feature of metastatic UM
tumors  [1],  ANLN  overexpression  could  create  defects  in
cytokinesis leading to binucleation and genomic instability.
Calcineurin  is  a  protein  phosphatase  regulating  the  Ca2+/
calmodulin  complex,  formed  by  a  catalytic  A  subunit
(PPP3CA) and a regulatory B subunit [17]. Whereas interest
was previously confined to its activity in immune response,
calcineurin is now becoming recognized as a predominant
participant in oncogenesis [18]. Indeed, the Ca2+/calcineurin/
nuclear factor of activated T-cells (NFAT) signaling pathway
influences  different  aspects  of  tumor  biology,  such  as
stimulation of angiogenesis through upregulation of vascular
endothelial growth factor (VEGF), tumor cell proliferation
through upregulation of myelocytomatosis oncogene (MYC),
and tumor cell migration through cyclooxygenase-2 (COX-2)
[18].  Native  PPP3CA  contains  five  distinct  domains:  the
NH2-terminal,  the  catalytic,  the  B-subunit  binding,  the
calmodulin-binding  and  the  auto-inhibitory  domains  [17].
Three  variants  were  identified  previously  and  one  splice
variant  showed  no  phosphatase  activity,  but  was  able  to
Figure 4. PPP3CA expression in UM.
A:  The  expression  level  of  PPP3CA
mRNA  was  measured  by  semi-
quantitative RT–PCR in the TP31 cell
line, UM primary tumors (Tumors), and
UVM. B: The expression level of the
PPP3CA  protein  was  measured  by
western blot in the TP31 cell line, UVM,
and UM primary tumors (left panel: pool
of  protein  extracts  from  UM  primary
tumors;  right  panel:  individual  UM
primary tumors). A new splice variant
was detected, which lacks parts of the
NH2-terminal  and  catalytic  domains
after  the  deletion  of  exon  2
(PPP3CAΔ2). The 18S rRNA was used
as internal control of amplification (489
bp). Actin was used as a protein loading
control. Data are representative of three
independent experiments.
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1331stimulate the phosphatase activity of the native protein, thus
rendering  PPP3CA  more  calcium-sensitive  [19].  In  the
present study, we reported the expression of a novel PPP3CA
splice  variant  in  primary  UM  cells  that  lacks  part  of  the
NH2-terminus  and  catalytic  domains  (PPP3CAΔ2;
GenBank#AY904364;  Figure  4).  Further  biochemical
analysis will be necessary to determine whether or not the
catalytic activity of this new variant is altered.
Among the genes found to be downregulated in the UVM
subtracted library, several were previously associated with
melanoma, such as melanocytic markers TYRP1, EDNRB,
MTAP, and sex determining region Y box 4 (SOX4; Table 4).
Indeed, the expression of TYRP1 was inversely correlated
with tumor stage in malignant melanoma [20]. A decreased
expression of EDNRB was previously associated with early
metastasis and short survival in UM [21]. A tissue microarray
study  in  malignant  melanoma  demonstrated  a  significant
reduction of MTAP in melanomas and metastases compared
with nevi [22]. In addition, SOX4 expression was reduced in
metastatic  malignant  melanoma  compared  with  dysplastic
nevi  and  primary  melanoma.  SOX4  downregulation  was
correlated  with  a  poor  prognosis  and  SOX4-depleted
melanoma  cells  showed  enhanced  invasion  and  migration
[23].
SSH technique was previously used in efforts to identify
genes that were differentially expressed in UM [21,24,25].
One  study  was  aiming  to  identify  genes  involved  in  the
development of metastases [21] whereas the other studies
were  rather  aiming  to  identify  genes  that  are  involved  in
malignant transformation of melanocytes [24,25]. Only a very
small number of genes were reported by these studies as a
result of the analysis of their subtracted library [21,24,25]. As
a consequence, an extensive comparison between our results
and their data could not be performed. Among the four genes
they reported, namely the cysteine-rich protein 61 (CYR61)
and tissue factor (also called coagulation factor III), EDNRB
and the AXL receptor tyrosine kinase (AXL), only EDNRB
was identified in our UVM subtracted library [21,24,25].
One limitation of the present study is the use of only one
primary UM cell line for the preparation of the SSH libraries.
However,  the  validation  of  the  SSH  list  of  genes  by
microarray, semi-quantitative RT–PCR and western blot with
primary tumor samples compensated for the use of only the
TP31 cell line as starting material. It is noteworthy that the
TP31 cell line is devoided of the GNAQ/GNA11 mutations and
that, consequently, the genes reported in the present study
could allow to establish a new mechanism for early gene
expression changes leading to malignant transformation and
proliferation of uveal melanocytes. Consistent data have been
obtained when comparing the SSH results with microarray
data  and  RNA/protein  extracts  of  primary  UM  tumors,
suggesting that UM cell lines could represent good models for
such analyses given the limited availability of primary UM
tumor samples. Studying the function of these genes and their
biologic  pathways  may  lead  to  the  development  of  new
therapeutic options.
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